AtriCure, Inc. (ATRC)

NASDAQ

$41.05

-$1.33 (3.14%)

Today

No price data available for this timeframe.

Key Statistics

Day Range

$41.02$42.60

Open $42.40

52 Week Range

$28.29$43.11

Previous Close $42.38

Market Cap2.04B

Volume474.21K

Avg Volume509.72K

P/E (TTM)-68.03

EPS (TTM)$-0.60

Dividend / YieldN/A

Dividend StreakN/A

Latest Press Releases for AtriCure, Inc.

DEC112025

AtriCure Announces the First Patients Treated with Novel Dual Energy Platform

Source: Business Wire•4 days ago

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced successfu...

NOV182025

AtriCure to Participate in the Piper Sandler 37th Annual Healthcare Conference

Source: Business Wire•27 days ago

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the...

OCT292025

AtriCure Reports Third Quarter 2025 Financial Results; Raises Financial Outlook for 2025

Source: Business Wire•47 days ago

OCT282025

AtriCure Announces the First Patient Treated in the BoxX-NoAF Clinical Trial

Source: Business Wire•48 days ago

OCT272025

AtriCure to Participate in Upcoming Investor Conferences

Source: Business Wire•49 days ago

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the...

OCT82025

AtriCure to Announce Third Quarter 2025 Financial Results

Source: Business Wire•68 days ago

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it ...

Latest Press Releases for AtriCure, Inc.

DEC112025

AtriCure Announces the First Patients Treated with Novel Dual Energy Platform

Source: Business Wire•4 days ago

NOV182025

AtriCure to Participate in the Piper Sandler 37th Annual Healthcare Conference

Source: Business Wire•27 days ago

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the...

OCT292025

AtriCure Reports Third Quarter 2025 Financial Results; Raises Financial Outlook for 2025

Source: Business Wire•47 days ago

OCT282025

AtriCure Announces the First Patient Treated in the BoxX-NoAF Clinical Trial

Source: Business Wire•48 days ago

OCT272025

AtriCure to Participate in Upcoming Investor Conferences

Source: Business Wire•49 days ago

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the...

OCT82025

AtriCure to Announce Third Quarter 2025 Financial Results

Source: Business Wire•68 days ago

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it ...